fluorouracil thermosensitive hydrogel

This investigational formulation of the antimetabolite fluorouracil (5-FU) is designed for local colonic delivery in patients with colorectal cancer. Developed by The Second Hospital of Nanjing Medical University, the treatment utilizes a thermosensitive hydrogel composed of poloxamer 407 and poloxamer 188 as a drug carrier. The formulation is engineered to remain in a liquid state at room temperature for ease of administration via transendoscopic enteral tubing and transitions into a gel state at body temperature. This phase transition enhances local adhesion to the colonic mucosa and facilitates the sustained release of 5-FU directly to the tumor site. By providing targeted delivery, this approach aims to maximize therapeutic efficacy while reducing the systemic toxicities typically associated with intravenous 5-FU chemotherapy. The active ingredient, 5-FU, exerts its effect by inhibiting thymidylate synthase, thereby interfering with DNA synthesis and cell proliferation.

Other names

5-fluorouracil thermosensitive hydrogel5-FU thermosensitive hydrogelColonic local administration of fluorouracil with enhanced adhesion